α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.

ABSTRACT:

Objective

Progressive accumulation of α-synuclein (α-syn) has been associated with Parkinson's disease (PD) and Dementia with Lewy body (DLB). The mechanisms through which α-syn leads to neurodegeneration are not completely clear; however, the formation of various oligomeric species have been proposed to play a role. Antibody therapy has shown effectiveness at reducing α-syn accumulation in the central nervous system (CNS); however, most of these studies have been conducted utilizing antibodies that recognize both monomeric and higher molecular weight α-syn. In this context, the main objective of this study was to investigate the efficacy of immunotherapy with single-chain antibodies (scFVs) against specific conformational forms of α-syn fused to a novel brain penetrating sequence.

SUBMITTER: Spencer B 

PROVIDER: S-EPMC4999592 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature